Roidipedia.Compound reference & reporting
05 AUG 2026
CompoundsPeptide Sermorelin
PeptideInjectablePeptideGHRH analogueSecretagogue

Sermorelin

Also known as Sermorelin · GHRH(1-29) · Geref · GRF 1-29

Sermorelin is GHRH(1-29), the shortest fully active fragment of growth-hormone-releasing hormone. It was an FDA-approved product (Geref) used as a diagnostic agent for GH secretion and to treat childhood GH deficiency before being discontinued for commercial reasons. It stimulates pulsatile endogenous GH release and is now popular in anti-ageing/wellness clinics. Human data exists but is older.

01 Overview

As native GHRH(1-29), sermorelin binds the pituitary GHRH receptor to promote synthesis and pulsatile release of growth hormone, preserving feedback regulation. Its clinical history as a diagnostic and paediatric therapy gives it more human evidence than most secretagogues, though the branded product is no longer marketed.

It is short-acting and dosed at night to mirror physiological GH pulses. Wellness use targets sleep, recovery and body composition; efficacy for these in healthy adults is modest and not rigorously established.

02 Mechanism

GHRH(1-29) analogue that activates the pituitary GHRH receptor, stimulating synthesis and pulsatile secretion of endogenous growth hormone with intact negative feedback.

03 Dosing

TierDoseRouteNotes
Wellness/anti-ageing (off-label)100–500 mcg/daySubQTypically dosed at bedtime; historical diagnostic dose was ~1 mcg/kg IV.

04 Effects

EffectMagnitudeEvidence
Raised GH and IGF-1Stimulates pulsatile GH release; used clinically as a provocative test of pituitary GH reserve.Clinical
Improved sleepBedtime dosing reportedly improves sleep quality, consistent with GHRH's role in slow-wave sleep.Observational
Fat loss and recoveryReported modest body-composition and recovery benefits in wellness use; not rigorously established.Anecdotal

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
Injection-site reactionsLocal redness, pain or swelling, the most frequent reaction in trials.MildCommonClinical
Flushing / transient dizzinessFacial flushing, headache or light-headedness after dosing.MildUncommonClinical
Mild water retentionSlight fluid retention or wrist tingling from GH elevation.MildUncommon at typical dosesAnecdotal

07 References

Sermorelin (GHRH 1-29) in diagnosis and treatment of GH deficiencyPubMed
GHRH(1-29) and slow-wave sleepPubMed search

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.